49 results
8-K
EX-1.1
SABS
SAB Biotherapeutics Inc
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
be the sole responsibility of the Company and that the Agent shall have no obligation in connection with such compliance. The offer and sale
424B5
SABS
SAB Biotherapeutics Inc
26 Jan 24
Prospectus supplement for primary offering
4:00pm
no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume … act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under
8-K
EX-10.1
SABS
SAB Biotherapeutics Inc
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
responsibility for the matter or matters that are the subject of the statement.
“Company Party” has the meaning set forth in Section 4.15(c)(ii … of the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company
424B3
g2oqj985t0zymp tbk
29 Apr 22
Prospectus supplement
4:16pm
POS AM
ftoqtzhmeaswxrdk7e2f
20 Apr 22
Prospectus update (post-effective amendment)
4:56pm
424B3
s668 hz5m3cxopz
29 Dec 21
Prospectus supplement
4:01pm
8-K
EX-10.1
ndz0d8sj
19 Nov 21
Entry into a Material Definitive Agreement
4:49pm
8-K
EX-10.6
d7ckcwk0w
28 Oct 21
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-3.2
2gekh85l
28 Oct 21
Entry into a Material Definitive Agreement
5:16pm